National Comprehensive Cancer Network
- NCCN
Guidelines®- End User License Agreement
- NCCN Guidelines for
Treatment of Cancer by Site- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Anal Carcinoma
- Basal and Squamous Cell Skin Cancers
- Bladder Cancer
- Bone Cancer
- Breast Cancer
- Central Nervous System Cancers
- Cervical Cancer
- Chronic Myelogenous Leukemia
- Colon Cancer
- Dermatofibrosarcoma Protuberans
- Esophageal and Esophagogastric Junction Cancers
- Gastric Cancer
- NCCN Guidelines for Detection,
Prevention, & Risk Reduction - NCCN Guidelines for
Supportive Care - NCCN Guidelines for
Age Related Recommendations - NCCN Guidelines for Patients®
- International Adaptations & Translations
- NCCN Pocket Guidelines
- NCCN Disclosure Policies &
Potential Conflicts of Interest - Licensing and Permissions
- Stay up-to-date with
NCCN Flash Updates™ - NCCN Guidelines Apps
- NCCN
Compendia- End User License Agreement
- NCCN Compendium®
- NCCN Biomarkers Compendium™
- Subscribe to the NCCN Compendia
- Licensing and Permissions
- Subscriptions
& Products- NCCN Compendium
- NCCN Biomarkers Compendium
- NCCN Templates
- Combination Subscriptions
- NCCN Flash Updates™
- NCCN Flash Updates™ Coupons
- NCCN Trends™ Surveys & Data
- NCCN Academy Video Modules
- NCCN eBulletin Newsletter
- NCCN Health Information Technology Licensees
- JNCCN — Journal of the National Comprehensive Cancer Network
- Advertising Opportunities
- NCCN Online Catalog
- Clinical & Business
Resources- Members Only
- NCCN Corporate Council
- NCCN Academy
- NCCN Insights: Analytics, Research & Consulting
- NCCN Resource Tool: REMS
- NCCN Collaboration with the National Business Group on Health
- NCCN Virtual Reimbursement Resource Room
- NCCN Health Information Technology Licensees
- NCCN Oncology Policy Program White Papers
- NCCN Oncology Research Program (ORP)
- ORP Recent News
- NCCN ORP Affiliate Research Project
- ORP Scientific Publications
- ORP Investigator Steering Committee
- ORP Testimonials
- Clinical Trials at NCCN Member Institutions
- Find ORP Funded Clinical Trials at NCCN Member Institutions
- NCCN Specialized Imaging Research Consortium™ (SIRC)
- NCCN ORP Disclosure Policy
- NCCN ORP for Industry
- NCCN Informed Consent Language Database
- NCCN Content Policies
- Patient
Resources- NCCN Guidelines for Patients®
- NCCN Website for Patients and
Caregivers - NCCN.com - Find an NCCN Member Institution
- Find an NCCN Cancer Center Near You
- Information on Patient Assistance & Reimbursement Help
- NCCN Virtual Reimbursement Resource Room Guide
- Find Clinical Trials
- NCCN Foundation
- Donate to the NCCN Foundation
NCCN Research & Business Resources
Guidelines, Compendium for NHL Updated to Include Ofatumumab and Romidepsin
The NCCN Clinical Practice Guidelines in Oncology for Non-Hodgkin's Lymphomas (NHL) and the NCCN Drugs & Biologics Compendium chapter for NHL have been updated to include ofatumumab and romidepsin.
Ofatumumab was added to the NCCN Guidelines as a treatment option for relapsed/refractory disease in patients with chronic lymphocytic leukemia (CLL), with and without a 17p deletion.
In addition, the updated NCCN Guidelines now include romidepsin as a suggested systemic treatment option for patients with mycosis fungoides and Sézary syndrome, two of the most common types of cutaneous T-cell lymphoma (CTCL).
| Quick Links |
|
|
About NCCN| NCCN Member Institutions| Patient Resources| NCCN Foundation| Privacy Policy| Legal Notices| Contact Us
275 Commerce Drive, Suite 300, Fort Washington, PA 19034 • 215.690.0300 • Fax: 215.690.0260
Copyright © 2012 National Comprehensive Cancer Network, All Rights Reserved